INCB 62079

Drug Profile

INCB 62079

Alternative Names: INCB-062079; INCB-62079

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cholangiocarcinoma; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Ovarian cancer

Most Recent Events

  • 25 May 2017 Phase-I clinical trials in Cholangiocarcinoma in USA (unspecified route) (NCT03144661)
  • 25 May 2017 Phase-I clinical trials in Liver cancer (Late-stage disease) in USA (unspecified route) (NCT03144661)
  • 25 May 2017 Phase-I clinical trials in Nasopharyngeal cancer in USA (unspecified route) (NCT03144661)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top